期刊文献+

维生素K_2与骨质疏松 被引量:4

下载PDF
导出
摘要 维生素K2不仅与凝血功能有关,而且与骨代谢有关,对骨质疏松有预防和治疗作用。作者着重从维生素K的生理功能,对骨代谢的影响以及对骨质疏松的预防、治疗作用等方面来介绍近年来维生素K2在临床研究和应用中的进展。
出处 《四川省卫生管理干部学院学报》 2007年第4期293-295,共3页 Journal of Sichuan Continuing Education College of Medical Sciences
  • 相关文献

参考文献21

  • 1Sato T, Ohtani Y, Yamada Y, et al. Difference in the metabolism of vitamin K between liver and bone in vitamin K deficient rats, [J]. Br J Nutr, 2002; 87 (4): 307.
  • 2Bouxsein M I. Mechanisms of osteoporosis therapy a bone strength perspective [J]. Clinical Cornerstone, 2003; 5: 13.
  • 3JILKA R I, Biology of the basic muhicellular unit and the pathophysiology of osteopososis. Med Pediatr Oncol. 2003; 41 (3): 182.
  • 4赵新华.维生素K与骨代谢[J].国外医学(卫生学分册),1998,25(6):363-367. 被引量:8
  • 5Hara H, Kobayashi M, Akiyama Y. Vitamin K2 (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats [J]. Bone, 2002; 31 (5): 575.
  • 6腰原康子,骨形成,invitro石化におけるピタミソK2の作用机序[].Osteporosis Japan,1996;4(2):191.
  • 7Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vivro, [ J ]. J Bone Miner Res, 1997; 12 (3): 431.
  • 8郭洪敏,杜靖远.维生素K_2对成骨细胞增殖和分化的影响[J].中华老年医学杂志,1998,17(2):73-75. 被引量:16
  • 9Urayama S, Kawakami A, Nakashima T, etal. Effect of vitamin K2 on osteoblast apoptosis: Vitamin K2 inhibits apoptptic cell death of human osteoblasts induced by Fas proteasome inhibitor etopside and stanrosporine [J]. J Lab Clin Med, 2000; 136 (3): 181.
  • 10Kameda T, Miyazawa K, Mori Y, et al. VitaminK2 inhibits Osteoclastic bone resorption by inducing osteoclast apoptosis [ J]. Biochem Biophys Res Commun, 1996; 220: 515.

二级参考文献9

  • 1陶天遵,陶树青,吕嵩,尹文哲,张风云,乔振海,吴振铎,边晓燕,李月部.维生素K_3对去卵巢大鼠骨质疏松预防作用的实验研究[J].中国骨质疏松杂志,1996,2(2):27-29. 被引量:13
  • 2Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Aging Clin Exp Res, 2000,12: 1-12.
  • 3Orwall E,Ettinger M,Weiss S, et al. Alendronate for the treatment of osteoporosis in men. NEJM, 2000,343: 604-610.
  • 4Hochberg M. Preventing fractures in postmenopausal women with oateoporosis. Drugs Aging, 2000,17: 317-330.
  • 5Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab, 2000, 85: 4118-4124.
  • 6Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with poatmenopausal osteoporosis: a randomized controlled trial. JAMA, 1999,282: 1344-1352.
  • 7Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effects of fisedronate on vertebral fractures in women with established postmenopausal osteoporosis. Ostoporosis Int, 2000, 11 : 83-91.
  • 8王洪复,上海医科大学学报,1991年,18卷,475页
  • 9林华,韩祖斌,孙燕芳,陈新,谢力,魏海燕.骨吸收抑制剂治疗绝经后骨质疏松的临床评价[J].江苏医药,2002,28(8):566-568. 被引量:13

共引文献44

同被引文献147

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部